The researchers analyzed data on 1,331 patients who underwent 1,461 abdominal surgeries between January 1998 and June 2014.
Patients who received at least one narcotics prescription within a month before surgery accounted for 18.3 percent of the study. These patients were prone to be smokers, have perianal disease and receive biologics therapy, and they stayed in the hospital an average of 11.2 days. Meanwhile, their counterparts who did not use narcotics preoperatively averaged 7.7 days. Forty-three percent of all patients experienced some form of complication, but in the narcotic users the rate jumped to 52.8 percent. Preoperative narcotic use was significantly related to five deaths.
These findings bear significance due to the endemic narcotic use of patients with Crohn’s disease for pain management and other reasons. The researchers suggest earlier consideration for surgery should be given before initiating a long-term opioid treatment in patients with abdominal Crohn’s disease.
More articles on quality:
New study ties paid family leave to reduced hospital admissions for children
Treating high blood pressure may be dangerous for diabetics
Old wool dye shows potential as cancer drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
